Description: Cue Biopharma Inc is a biopharmaceutical company developing a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders.
Home Page: www.cuebiopharma.com
CUE Technical Analysis
21 Erie Street
Cambridge,
MA
02139
United States
Phone:
617 949 2680
Officers
| Name | Title |
|---|---|
| Mr. Daniel R. Passeri J.D., M.Sc., MSc. | CEO & Director |
| Dr. Anish Suri Ph.D. | Pres & Chief Scientific Officer |
| Ms. Kerri-Ann Millar | Chief Financial Officer |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo J. Chaparro | Co-Founder & Sr. Advisor |
| Dr. Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board |
| George B. Zavoico Ph.D. | VP of Investor Relations & Corp. Devel. |
| Mr. Colin G. Sandercock J.D., MSE | Sr. VP, Gen. Counsel & Sec. |
| Dr. Kenneth J. Pienta M.D. | Acting Chief Medical Officer |
| Dr. Matteo Levisetti M.D. | Sr. VP of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5013 |
| Price-to-Sales TTM: | 13.0301 |
| IPO Date: | 2018-01-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |